Pfizer Inc. (PFE)
|Net Income (ttm)||11.09B|
|Trading Day||July 29|
|Day's Range||42.62 - 43.30|
|52-Week Range||32.74 - 43.35|
The company posted great Q2 results. But its future prospects look even brighter than it's saying.
Pfizer developing a pill to treat Covid
CNBC's Meg Tirrell reports that Pfizer is going full-speed ahead to develop a pill that will treat Covid in its early stages.
Ford, Shopify, Microsoft, Pfizer and Tilray were our top stock trades for Thursday. That said, let's get a look at the charts now.
Pfizer sees 10% operational growth with Covid vaccine
Meg Tirrell joins The Exchange to discuss Pfizer's most recent earnings report and their proposed antiviral Covid pill. They hope to have preliminary results from trials by the end of the year.
Covid immunity wanes 6 months after the Pfizer vaccine
Pfizer CEO Albert Bourla joins The Exchange to discuss new developments with his company's Covid vaccine, one of the two mRNA vaccines approved for emergency use in the U.S. The company is reporting new...
The company's powerful growth isn't only due to its coronavirus vaccine.
Pfizer beats on earnings, raises 2021 guidance on vaccine sales
Yahoo Finance's Anjalee Khemlani on Pfizer's latest earnings call and raised projected revenue for 2021. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-Ozw...
Pfizer's vaccine initially protects people 100% of the time against hospitalization, but that falls to low 90% and mid-to-high 80% after six months, Bourla said
Based on its earnings report, Pfizer (PFE) raised estimated sales of its Covid-19 vaccine to $33.5 billion for 2021, reflecting a 30% increase as Delta sweeps through nations, reports The Wall Street Jo...
Third Dose Of Pfizer-BioNTech's COVID-19 Vaccine Boosts Protection Against Delta Variant, New Data Reveals
A third dose of the Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine can "strongly" boost protection against the delta variant beyond the protection afforded by the standard two dose...
Boeing (BA) posted a surprise profit in Q2, and shares are up over 5% in pre-market trading as a result.
Pfizer Inc., (NYSE: PFE) announced that the company sold Covid-19 jabs worth $7.8 billion in the second quarter. In addition, the company raised its full-year 2021 sales estimates from the vaccine from ...
These defensive stocks are worth adding to your portfolio as the market looks overvalued and a sharp correction seems likely. The post 7 Defensive Stocks to Buy for an Upcoming Market Crash appeared fir...
Pfizer expects to deliver 2.1 billion doses of its COVID-19 vaccine in 2021, with plans to manufacture a total of 3 billion by the end of 2021.
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It lifts its guidance for 2021.
So what will the stock market do today? All eyes are on Chinese stocks and on the spreading Delta Covid-19 variant.
Pfizer Inc. (NYSE: PFE) shares were trading about 2.1% higher at $42.99 per share after the company reported better-than-expected Q2 EPS and sales results. The company also raised its full-year 2021 ear...
Pfizer sold a staggering $7.8 billion worth of coronavirus jabs during the second quarter — and predicted its profits will continue to explode as the Delta variant spurs fresh demand for booster shots.
Pfizer (PFE) delivered earnings and revenue surprises of 10.31% and 8.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Pfizer Inc. (NYSE:PFE) reported second-quarter earnings of $1.07 per share, which was better than the estimates of 98 cents. The company also raised full-year guidance to $3.95 to $4.05.
Pfizer's Q2 earnings and revenue exceeded analysts' expectations.
Pfizer executed earnings well: Hightower's Link
CNBC's "Squawk Box" team discusses markets and earnings with Stephanie Link of Hightower.
Pfizer beats earnings expectations, raising full-year guidance
CNBC's Meg Tirrell reports on Pfizer's earnings results.
Shares of Pfizer (NYSE:PFE) moved higher by 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 37.18% over the past year to $1.07, which bea...
Pfizer Inc (NYSE: PFE) reports Q2 adjusted EPS of $1.07, well ahead of the consensus of $0.96 and 73% Y/Y higher from $0.62 posted a year ago. The Company achieved Q2 revenues of $18.9 billion, +92% Y/...
Pfizer said Wednesday it is raising the 2021 sales forecast of its Covid-19 vaccine to $33.5 billion from $26 billion.
(Reuters) -Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine that it developed with Germany's BioNTech by 28.8% to $33.5 billion, as countries scramble to secure supply of th...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2021 and raised 2021 guidance(4) for revenues and Adjusted diluted EPS(3) driven by its updated expectati...
The writing could already be on the wall.
FDA Requests Pfizer and Moderna to Expand Pediatric Trials
The Food and Drug Administration has requested Pfizer and Moderna to test their COVID vaccines in more children before seeking authorization to help rule out safety issues. The expanded pediatric trials...
Pharma Heavyweights, Including Pfizer And JNJ Trying To Push Global Tax Deal Amid COVID-19 Role: WSJ
In the face of a comprehensive global tax agreement intended to inhibit tax avoidance opportunities, industry executives and lobbyists are mounting a quiet campaign to push back against the measure, the...
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pfizer (PFE) reports Q2 earnings before market open on July 28. Can it maintain soaring earnings and revenue growth amid the global COVID-19 pandemic?
Pfizer (NYSE: PFE) is scheduled to report its Q2 2021 results on Wednesday, July 28. We expect the company to likely post revenue and earnings well above the consensus estimates, primarily led by its Co...
The giant drugmaker just landed another big supply deal.
The study follows another by Oxford University that found taking an AstraZeneca vaccine shot followed by a Pfizer shot created a high immune repsonse.
The studies aim to spot rare side effects of the COVID-19 vaccine in younger recipients.
Pfizer And Moderna Reportedly Expanding Covid Vaccine Studies Of Children To Better Understand Rare Side Effects
The vaccine makers were reportedly asked by the Food and Drug Administration to expand the size of their ongoing trials.
Pfizer Inc (NYSE:PFE) – BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) will expand the size of ongoing COVID-19 vaccine trials in children ages five to 11 to detect potential rare side effects,...
The five largest U.S. traded companies report June-quarter earnings this week, beginning Monday evening with Tesla.
All eyes are on Pfizer versus the delta variant.
Once again, their high efficacy could mean more market share.
We hope this mid-year letter finds you, your family, and your colleagues healthy and well. Here in Boston, GMO's headquarters, the streets are filling up with summer tourists, restaurants are crowded, o...
Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the second quarter.
Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas.
The federal government has bought an additional 200 million COVID-19 vaccine doses that are expected to be delivered starting in October 2021.
It's little surprise that some of the companies behind the Covid-19 vaccines have seen their stocks rise. Here's how investors can benefit.
Pfizer Shot Just 39% Effective Against Delta Infection, But Largely Prevents Severe Illness, Israel Study Suggests
Previous estimates indicated the Pfizer shot was only moderately less protective against Delta, though all studies indicate a high level of protection against hospitalization and severe illness.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brand... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, Pfizer's revenue was $41.91 billion, an increase of 1.79% compared to the previous year's $41.17 billion. Earnings were $9.62 billion, a decrease of -40.91%.
According to 21 analysts, the average rating for Pfizer stock is "Buy." The 12-month stock price forecast is 43.32, which is an increase of 1.24% from the latest price.